AINEWS
A two-step strategy added 70% to mouse lifespans
The approach trains the immune system to clear senescent cells, sometimes called "zombie cells," then injects personalized stem cells. Whether it translates to people remains the open question.
The approach trains the immune system to clear senescent cells, sometimes called "zombie cells," then injects personalized stem cells. Whether it translates to people remains the open question.
Researchers report training the immune system to clear aging-related senescent cells, sometimes called "zombie cells," and then injecting personalized stem cells to repair the tissue damage that follows. In mice, the two-step sequence extended lifespan by more than 70 percent, according to a joint announcement from the two companies behind the work. Whether the same trick works in humans is the question this study cannot yet answer.
The result was announced on June 15 by Immorta Bio, whose president, Thomas Ichim, and TAM Global, whose chief scientific officer is Francesco M. Marincola. The two companies say they paired Immorta Bio's SenoVax platform, a senolytic immunotherapy designed to selectively eliminate senescent cells, with TAM Global's StemCellRevivify, a personalized mesenchymal stem cell platform meant to restore tissue function. Their press release frames the result as a "breakthrough" in a "first-in-class, dual-modality" anti-aging strategy.
The order matters, both companies argue. The release describes a sequential design: clear the senescent cells first, then introduce the regenerative cells. Ichim said in the release that the order "amplifies the benefit of both components" and produces effects that exceed what either platform achieves alone. Treated animals were also reported to show sustained improvements in "physiological performance," though the release does not define that term or specify the metrics, mouse strain, age, sex, or statistical method used.
The collaborators named in the release include the Buck Institute for Research on Aging, the University of Miami, Cedars-Sinai Medical Center, the University of San Diego, George Washington University Medical Center, BioCenturium, and Stanford, all listed as contributors to the broader program. None of those institutions is quoted independently in the release, and no peer-reviewed paper, DOI, preprint, or independent expert is cited. The "70 percent" figure, the specifics of the study design, and the "first-in-class" claim all rest on the company announcement rather than third-party verification. That makes the result a data point worth tracking, not a finding to act on.
The translation gap is also large and well documented. Mouse studies of anti-aging interventions have a long record of failing to translate to humans, and the senolytic category is no exception. The senolytic-plus-regenerative combination Immorta Bio and TAM Global describe is biologically plausible, and the field is active: groups at the Mayo Clinic, UNITY Biotechnology, and other academic and industry labs have been pursuing senolytic strategies for years. None has yet produced a peer-reviewed human result that matches the kind of headline number the two companies reported this week.
The next checkpoint is publication. If the SenoVax plus StemCellRevivify result holds up under peer review, the field will want to see effect size, mouse strain and age, controls, and replication by an independent lab. If it does not, the result is likely to sit alongside a long list of mouse-stage anti-aging claims that did not survive contact with human biology. Either way, the "70 percent" will be measured against what comes next, not against what the press release says today.